Before potential implementation in the clinical practice, further studies should therefore validate which commercially available assays are the most sensitive and reliable in the detection of a serum pool of survivin in MM patients and have higher predictive values in serum samples. This evidence concerns the gene BIRC5 and Miyoshi myopathy.